July 31, 2024 07:09 AM EDTUpdated 10:54 AM

Takeda takes $140M hit on Phase 3 epilepsy flop, previews late-stage trials for pipeline prospects

Amber Tong

Takeda is registering a JPY $21.5 billion ($140 million) impairment on its Ovid-licensed epilepsy drug in light of negative Phase 3 results, the Japanese drugmaker …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda takes $140M hit on Phase 3 epilepsy flop, previews late-stage trials for pipeline prospects

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win

Take­da takes $140M hit on Phase 3 epilep­sy flop, pre­views late-stage tri­als for pipeline prospects

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

Takeda takes $140M hit on Phase 3 epilepsy flop, previews late-stage trials for pipeline prospects

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win